Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease

Purpose Fluvoxamine (FVX) is metabolized by cytochrome P450 (CYP) 2D6 and CYP1A2 and inhibits CYP3A4. The aim of this study was to investigate the factors responsible for interindividual variability in the extent of interaction between FVX and alprazolam (ALP). Methods Blood samples were taken from...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of clinical pharmacology 2009-07, Vol.65 (7), p.699-704
Hauptverfasser:	Sugahara, Hideyo, Maebara, Chiharu, Ohtani, Hisakazu, Handa, Masanori, Ando, Katsumi, Mine, Kazunori, Kubo, Chiharu, Ieiri, Ichiro, Sawada, Yasufumi
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult and adolescent clinical studies Alleles Alprazolam Alprazolam - blood Alprazolam - therapeutic use Antidepressants Biological and medical sciences Biomedical and Life Sciences Biomedicine CYP2D6 Cytochrome P-450 CYP2D6 - genetics Dose-Response Relationship, Drug Drug interaction Drug Interactions - genetics Fluvoxamine Fluvoxamine - blood Fluvoxamine - therapeutic use Genotype Genotype & phenotype Humans Medical sciences Pharmacokinectics and Disposition Pharmacology Pharmacology. Drug treatments Pharmacology/Toxicology Polymorphism Polymorphism, Genetic - drug effects Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychophysiologic Disorders - drug therapy Psychophysiologic Disorders - genetics Psychotropic drugs Serotonin Uptake Inhibitors - blood Serotonin Uptake Inhibitors - therapeutic use Smoking Smoking - metabolism Somatoform disorders. Psychosomatics Tobacco, tobacco smoking Toxicology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!